• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

作者信息

Ridker Paul M

机构信息

Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.

出版信息

Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. doi: 10.1093/cvr/cvab231.

DOI:10.1093/cvr/cvab231
PMID:34352102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8861265/
Abstract
摘要

相似文献

1
From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?从RESCUE到ZEUS：泽布替尼单抗抑制白细胞介素-6对降低心血管事件是否有效？
Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. doi: 10.1093/cvr/cvab231.
2
Inflammation and cardiovascular diseases: lessons from seminal clinical trials.炎症与心血管疾病：来自重要临床研究的启示。
Cardiovasc Res. 2021 Jan 21;117(2):411-422. doi: 10.1093/cvr/cvaa211.
3
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.炎症在动脉粥样硬化发病机制中的作用及治疗干预。
Atherosclerosis. 2018 Sep;276:98-108. doi: 10.1016/j.atherosclerosis.2018.07.014. Epub 2018 Jul 25.
4
Immunotherapy for cardiovascular disease.免疫疗法治疗心血管疾病。
Eur Heart J. 2019 Dec 21;40(48):3937-3946. doi: 10.1093/eurheartj/ehz283.
5
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.在高动脉粥样硬化风险患者中使用 ziltivekimab 抑制白介素-6（RESCUE）：一项双盲、随机、安慰剂对照、2 期试验。
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.
6
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.白细胞介素-6 信号转导与抗白细胞介素-6 治疗在心血管疾病中的应用
Circ Res. 2021 May 28;128(11):1728-1746. doi: 10.1161/CIRCRESAHA.121.319077. Epub 2021 May 17.
7
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.抗细胞因子药物：针对白细胞介素信号通路的抗动脉粥样血栓形成治疗。
Circ Res. 2019 Feb;124(3):437-450. doi: 10.1161/CIRCRESAHA.118.313129.
8
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.托珠单抗对白介素-6的治疗性阻断在AA型淀粉样变性和慢性炎症性疾病管理中的应用：病例系列及文献综述
Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S46-53. Epub 2015 Jun 29.
9
High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index.高全身性炎症作为一种新的心血管风险因素和抗细胞因子治疗的靶点：关于甘油三酯葡萄糖指数的评论。
Int J Cardiovasc Imaging. 2024 Apr;40(4):945-948. doi: 10.1007/s10554-024-03046-6. Epub 2024 Apr 1.
10
Inflammation and atherosclerosis: what is on the horizon?炎症与动脉粥样硬化：未来发展趋势如何？
Heart. 2020 Jan;106(1):80-85. doi: 10.1136/heartjnl-2018-314230.

引用本文的文献

1
Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms-a comprehensive review.心血管-肾脏-代谢综合征中的炎症：关键作用及潜在机制——综述
Mol Cell Biochem. 2025 Sep 10. doi: 10.1007/s11010-025-05379-9.
2
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction.非他汀类降脂疗法的进展：心血管风险降低策略演变的叙述性综述
Am J Cardiovasc Drugs. 2025 Aug 30. doi: 10.1007/s40256-025-00762-9.
3
Advancements in research to mitigate residual risk of atherosclerotic cardiovascular disease.减轻动脉粥样硬化性心血管疾病残余风险的研究进展。
Eur J Med Res. 2025 Aug 12;30(1):735. doi: 10.1186/s40001-025-03006-3.
4
Key inflammatory players for infarcted mass and cardiac remodeling after acute myocardial infarction.急性心肌梗死后梗死心肌及心脏重塑的关键炎症相关因素。
Front Cardiovasc Med. 2025 Jul 18;12:1609705. doi: 10.3389/fcvm.2025.1609705. eCollection 2025.
5
Uric Acid, Colchicine and Chronic Inflammatory Diseases: A Cardiovascular Perspective.尿酸、秋水仙碱与慢性炎症性疾病：心血管视角
Metabolites. 2025 Jun 20;15(7):424. doi: 10.3390/metabo15070424.
6
Soluble urokinase plasminogen activator receptor and interleukin-6 improves prediction of all-cause mortality and major adverse cardiovascular events in Type 1 diabetes.可溶性尿激酶型纤溶酶原激活物受体和白细胞介素-6可改善1型糖尿病患者全因死亡率和主要不良心血管事件的预测。
J Intern Med. 2025 Sep;298(3):188-199. doi: 10.1111/joim.20108. Epub 2025 Jul 7.
7
Targeting inflammation in heart failure: evolving insights and future directions from randomized clinical trials.心力衰竭中的炎症靶向治疗：来自随机临床试验的新见解与未来方向
Heart Fail Rev. 2025 Jun 17. doi: 10.1007/s10741-025-10538-7.
8
Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists.关于高敏C反应蛋白检测（hsCRP）在动脉粥样硬化性心血管疾病中的认知：一项针对美国心脏病专家和肾病专家的调查
Future Cardiol. 2025 Jul;21(9):701-710. doi: 10.1080/14796678.2025.2514349. Epub 2025 Jun 3.
9
Contributions of Noncardiac Organ-Heart Immune Crosstalk and Somatic Mosaicism to Heart Failure: Current Knowledge and Perspectives.非心脏器官-心脏免疫串扰和体细胞镶嵌现象对心力衰竭的影响：当前认知与展望
Circ Res. 2025 May 23;136(11):1208-1232. doi: 10.1161/CIRCRESAHA.125.325489. Epub 2025 May 22.
10
A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure.全面综述：揭示炎症在心力衰竭病因中的作用
Heart Fail Rev. 2025 May 14. doi: 10.1007/s10741-025-10519-w.

本文引用的文献

1
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.在高动脉粥样硬化风险患者中使用 ziltivekimab 抑制白介素-6（RESCUE）：一项双盲、随机、安慰剂对照、2 期试验。
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.
2
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.白细胞介素-6 信号转导与抗白细胞介素-6 治疗在心血管疾病中的应用
Circ Res. 2021 May 28;128(11):1728-1746. doi: 10.1161/CIRCRESAHA.121.319077. Epub 2021 May 17.
3
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.白细胞介素 6 受体抑制在急性 ST 段抬高型心肌梗死患者中的随机临床试验。
J Am Coll Cardiol. 2021 Apr 20;77(15):1845-1855. doi: 10.1016/j.jacc.2021.02.049.
4
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.抗细胞因子药物：针对白细胞介素信号通路的抗动脉粥样血栓形成治疗。
Circ Res. 2019 Feb;124(3):437-450. doi: 10.1161/CIRCRESAHA.118.313129.
5
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.卡那奴单抗的抗炎治疗预防心力衰竭住院。
Circulation. 2019 Mar 5;139(10):1289-1299. doi: 10.1161/CIRCULATIONAHA.118.038010.
6
Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study.应用炎症和肾功能指标预测 CKD 患者的动脉粥样硬化性血管疾病事件和死亡：来自 CRIC 研究的结果。
Am J Kidney Dis. 2019 Mar;73(3):344-353. doi: 10.1053/j.ajkd.2018.09.012. Epub 2018 Dec 10.
7
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).白介素-6 信号通路的调节与动脉粥样硬化事件和全因死亡率的发生率：来自卡那单抗抗炎血栓形成结局研究（CANTOS）的分析。
Eur Heart J. 2018 Oct 7;39(38):3499-3507. doi: 10.1093/eurheartj/ehy310.
8
Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study.白细胞介素 6 受体变异与心血管疾病的关联：白细胞介素 6 受体阻断治疗的表型全基因组关联研究。
JAMA Cardiol. 2018 Sep 1;3(9):849-857. doi: 10.1001/jamacardio.2018.2287.
9
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.卡那奴单抗抑制白细胞介素-1β与慢性肾脏病患者的心血管结局。
J Am Coll Cardiol. 2018 May 29;71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490.
10
An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice.白细胞介素-6受体抗体抑制动脉粥样硬化小鼠的动脉粥样硬化。
Front Cardiovasc Med. 2017 Dec 22;4:84. doi: 10.3389/fcvm.2017.00084. eCollection 2017.